Natixis Advisors LLC Has $20.06 Million Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Natixis Advisors LLC boosted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 5.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 47,761 shares of the company’s stock after acquiring an additional 2,590 shares during the quarter. Natixis Advisors LLC owned 0.06% of IDEXX Laboratories worth $20,057,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. MorganRosel Wealth Management LLC bought a new stake in shares of IDEXX Laboratories in the first quarter worth $26,000. Hurley Capital LLC acquired a new position in IDEXX Laboratories during the 4th quarter worth about $29,000. Colonial Trust Co SC grew its position in shares of IDEXX Laboratories by 84.8% in the 4th quarter. Colonial Trust Co SC now owns 85 shares of the company’s stock valued at $35,000 after buying an additional 39 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. increased its stake in shares of IDEXX Laboratories by 55.6% in the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company’s stock valued at $35,000 after buying an additional 30 shares during the period. Finally, Itau Unibanco Holding S.A. increased its stake in shares of IDEXX Laboratories by 540.0% in the fourth quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company’s stock valued at $40,000 after buying an additional 81 shares during the period. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

IDXX has been the topic of a number of recent analyst reports. Wall Street Zen raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday, July 12th. Stifel Nicolaus boosted their price target on shares of IDEXX Laboratories from $510.00 to $540.00 and gave the stock a “hold” rating in a research report on Wednesday, July 2nd. Jefferies Financial Group initiated coverage on shares of IDEXX Laboratories in a research note on Tuesday, July 1st. They issued a “buy” rating and a $625.00 price objective on the stock. Morgan Stanley lifted their target price on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an “overweight” rating in a research note on Monday, May 5th. Finally, Leerink Partners upped their price target on shares of IDEXX Laboratories from $580.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, July 17th. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $557.88.

Insider Activity at IDEXX Laboratories

In related news, Director M Anne Szostak sold 1,260 shares of the company’s stock in a transaction that occurred on Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total transaction of $645,548.40. Following the transaction, the director directly owned 1,801 shares of the company’s stock, valued at approximately $922,724.34. This represents a 41.16% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.98% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Stock Up 0.2%

IDEXX Laboratories stock opened at $535.54 on Friday. The company has a market capitalization of $43.07 billion, a PE ratio of 49.50, a PEG ratio of 3.81 and a beta of 1.49. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $579.47. The firm’s fifty day moving average is $531.30 and its 200 day moving average is $471.80. The company has a quick ratio of 0.81, a current ratio of 1.16 and a debt-to-equity ratio of 0.31.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, beating the consensus estimate of $2.93 by $0.03. The firm had revenue of $998.43 million during the quarter, compared to the consensus estimate of $998.25 million. IDEXX Laboratories had a net margin of 22.76% and a return on equity of 57.35%. The business’s revenue was up 3.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.71 earnings per share. As a group, sell-side analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.